While I doubt very much that management agrees with lending shares, but I don't ask. In short my experience with other companies just tells me the management here is really quite typical of other biotechs.
Some companies are slightly more outspoken than NWBO, some less, but the worst, IMHO, are the ones who hype everything they do, but routinely fail, like CVM.
It's easy to keep saying that you believe your product will cure XXXX and when it fails say the exact same words about curing YYYY, all you have to do is a search and replace in every PR you issue with XXXX being replaced by YYYY.
Management here has run the gauntlet, sure others would have done it differently, some might have been more successful, but I have a feeling that far more would have gone belly up. LP has taken the company to the point where success should be acknowledged in a few weeks, or months. I believe she can take it to the point that she'll be judged to be among the top biotech CEO's in the world, and she'll be one of the wealthiest, but so will her investors.
Gary
Market Data 
Markets 
AI
